ClinicalTrials.gg
CompletedNCT03216330Updated Apr 8, 2026Results posted

Dyspareunia and Central Sensitization

An observational study in Endometriosis, Central Sensitisation and Dyspareunia, sponsored by BC Women's Hospital & Health Centre. Completed at 1 site in Canada. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by BC Women's Hospital & Health Centre · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
56
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

Background: Endometriosis affects 10% of reproductive aged females, and can have a negative impact on sexual quality of life. Endometriosis can cause pelvic pain with deep penetration during intercourse, as well as other sexual and non-sexual pains. This study will allow us to determine if an increase in sexual pain is related to central sensitization.

Purpose: The purpose of this study is to determine if there is an association between the severity of sexual pain and central sensitization in women with endometriosis.

Measurement tools: Data will be collected from the Clinic's Data Registry, an online questionnaire, a quantitative sensory test (QST) to measure pain-pressure threshold (PPT) as a marker of central sensitization, and daily entry to an online survey.

Primary Hypothesis: Central sensitization (measured by lower pain-pressure threshold) will be associated with an increased severity of deep dyspareunia, as well as a tenderness of the bladder/pelvic floor and depression, in women with endometriosis.

Read the detailed description

Background:

Endometriosis results from the presence of endometrial cells growing abnormally outside the uterus and affects approximately 10% of reproductive-aged females. Endometriosis can be associated with various types of pain such as: dysmenorrhea (painful cramps with menses), deep dyspareunia (pelvic pain with deep penetration during intercourse), dyschezia (painful bowel movements) and chronic pelvic pain. Few studies have explored the association between endometriosis and deep dyspareunia resulting in a limited understanding of how to treat deep dyspareunia. Deep dyspareunia is defined as pelvic pain with deep penetration and occurs in 50% of women with endometriosis at some time in their sexual lives. Deep dyspareunia has been shown to lower or cease intercourse, thus lowering self-esteem and resulting in negative effects on sexual functioning and interpersonal relationships.

A potential contributor to deep dyspareunia in women with endometriosis that is largely under-researched is the concept of central sensitization. Central sensitization is an amplification of nociceptive signaling that may result from prolonged pain causing sensitization of the dorsal horn neurons, which results in hyperalgesia (increased response to pain) and allodynia (response to pain when there normally would not be). A recent study, comparing cross-sectional data from suspected or surgically diagnosed endometriosis patients, suggested that bladder and pelvic floor tenderness may be markers of central sensitization. However, the linkage between the indirect markers of central sensitization and the presence of central sensitization requires confirmation. This link can be assessed through validated quantitative sensory testing (QST). Likewise, the association between central sensitization and deep dyspareunia may also be confirmed through QST. QST is an objective measurement tool to determine the presence and/or degree of sensory disturbances, by detecting the alterations in nociceptive pathways. For example, a low pain-pressure threshold (i.e., increased pain sensation) at healthy unaffected areas, as measured by QST, indicates central sensitization.

Purpose: To determine if deep dyspareunia is associated with central sensitization in women with endometriosis.

Research Question: Is deep dyspareunia associated with central sensitization assessed by decreased pain-pressure threshold?

Objectives:

Primary Objective:

  1. Examine the association between central sensitization and severity of deep dyspareunia.

Secondary Objectives:

  1. Examine the association between central sensitization and severity of non-sexual pains and Endometriosis Health Profile (EHP-30) scores.
  2. Examine the association between central sensitization and tenderness of the bladder and pelvic floor (determined by physician on physical exam).
  3. Examine the association between central sensitization and psychological measures (assessed by validated questionnaires).

    Research Hypotheses:

    Primary Hypothesis: Central sensitization (measured by pain-pressure threshold) is associated with an increased severity of deep dyspareunia, as well as a tenderness of the bladder/pelvic floor and depression, in women with endometriosis.

    Secondary Hypothesis: Women with endometriosis will have greater central sensitization (indicated by a lower pain-pressure threshold) than women without endometriosis.

    Setting: The Pelvic Pain and Endometriosis program at the BC Women's Health Centre uses an interdisciplinary approach to managing pain, including: physiotherapy for bladder and pelvic floor, surgical intervention, pain education and medical management. This program addresses multiple factors influencing pain through multiple approaches, as opposed to the traditional approach of surgical removal of the endometriosis to resolve the pain alone.

    Design: This study is a longitudinal, prospective cohort study, involving cases and controls.

    Primary Outcome: Severity of deep dyspareunia (0-10 numeric rating scale)

    Secondary Outcomes: Severity of superficial dyspareunia, severity of non-sexual pains, and psychological questionnaire scores

    Main Independent Variables: Central sensitization measured by pain-pressure threshold (PPT) determined through QST

    Study Population: The case population includes women who have consented to the Data Registry (H16-00264) and who are newly or re-referred to the BC Women's Centre for Pelvic Pain and Endometriosis, and who have regardless of the severity of deep dyspareunia, either: 1) previous surgical diagnosis of endometriosis or 2) current ovarian endometrioma cyst or 3) current endometriosis nodule.

    Sample Size: 30 cases and 15 controls.

    Recruitment and Data Collection prior to Test date:

    Cases:

    • At the end of their appointment with one of the endometriosis specialists at the BC Women's Centre for Pelvic Pain and Endometriosis, the physician will ask the patient if they are interested in learning more about this research study (if the physician deems them acceptable to be included based on screening of inclusion and exclusion criteria), and if so, will tell them a research assistant may call them.
    • A poster introducing the study will also be available in the clinic waiting rooms.
    • During a phone conversation, research team will remind the potential case participant that they have consented to the data registry, and consent to this study allows us access to analyze their data registry data. Verbal consent will be given if the potential case participant would like to participate, and a test appointment will be booked.
    • Case participants will sign the consent form in-person at the beginning of the test day appointment.

    Control:

    • Recruitment of the control group will be done by poster advertisement, as well as an in-person information session at the BC Women's Hospital. If they are interested in the study, potential participants will be asked to contact the research team to learn more about the study.
    • Research team will provide the potential control participant with a copy of the consent form (in person or by email). Each potential control participant will be advised to carefully read the consent form, and to contact the research team with any questions about the information contained in the consent form.
    • If the control participant expresses interest in the study after reading the consent form, a link to access the screening questions will be sent to them.
    • Criteria will be assessed by screening questions. If the participants are eligible based on the screening questions then they will be asked if they would like to consent to the study (online consent). This online consent allows access to the data from the screening questions. If they are not eligible, or do not consent to the study their screening questions will not be analyzed. If the control participant consents online they will be asked to complete additional questions (height, etc.).
    • Research team will receive an email once the control participant has consented online, and will contact the participant to book an appointment.
    • On the test day, the consent participants will sign the same consent form in-person to consent to the testing procedures.

    Procedures for Data Collection (on Test day)

    Questionnaire:

    Case and Control:

    • An online questionnaire will collect data such as: score of sexual and non-sexual pains, first day of last menstrual period,etc. The pelvic pain questions asked on this online questionnaire are modified from the Brief Pain Inventory Short Form. This questionnaire will be filled out online during the test appointment.

    Quantitative Sensory Testing (QST):

    Case and Control:

    • After the questionnaire has been completed, the participants will undergo QST to measure their pressure-pain threshold (PPT), the point where the sensation of pressure has changed to the sensation of pain. Before testing begins, it will be made clear that the participants can withdraw from the study even during the procedure if they find it too uncomfortable.
    • The PPT data will be written down on a paper copy with the unique study ID, and entered into an encrypted excel file.
    • The observation made by this QST is that a lower PPT is suggestive of increased central sensitization.

    Feedback Questionnaire:

    Case and Controls:

    • After the participant's PPT has been measured, they will be given an anonymous feedback form to assess the procedure mechanisms and specifications, as well as comfort level before, during and after testing. This will allow investigators to adjust any necessary procedure details to create a more comfortable environment/test for future participants.

    Procedures for Data Collection (after Test day)

    Online Survey:

    Cases only:

    • Case participants will be asked to record study data daily for six weeks after their scheduled test date.
    • The data collected, will allow for daily prospective pain scores, rather than retrospective recollections of pain scores.

    Participants without email addresses will have the opportunity to complete the surveys on a printed out copy (given to them on the appointment day) and mail/bring in-person to the Centre at the end of the 6 weeks.

02

Conditions studied

  • Endometriosis
  • Central Sensitisation
  • Dyspareunia

Keywords

  • Quantitative sensory test (QST)
  • Deep dyspareunia
  • Electronic Thimble Algometer
03

In context

Endometriosis

920 studies on the registry are indexed under Endometriosis; 266 are open to participants now.

This study's enrollment of 56 is below the median of 135 across 349 observational studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

BC Women's Hospital & Health Centre is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Tertiary care centre (BC Women's Health Centre for Pelvic Pain and Endometriosis) for case participants.

Community sample for control participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Case:

    • Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.
    • New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.
    • Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)
    • Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.
    • At least 18 years old
  • Control:

    • Reproductive aged female with no suspected or diagnosed endometriosis.
    • Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.
    • At least 18 years old

Exclusion criteria

Exclusion Criteria:

- Case and Control:

  • Fibromyalgia.
  • Severe and enduring psychological illness(es) affecting cognition (e.g., bipolar disorder, schizophrenia etc.).
  • Currently pregnant or breastfeeding.
  • Have a peripheral or central neurological disorder.
  • Have diabetes mellitus or neuropathic pain.
  • Do not speak English.
  • Have had previous physical trauma (ex. Surgery) to the test site(s) (deltoid muscle in the shoulder, and first dorsal interosseous muscle).
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
56 participants (actual)
Patient registry
No

Groups and cohorts

  • Case

    * Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre. * New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis. * Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule) * Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date. * At least 18 years old

    Other: No Intervention

  • Control

    * Reproductive aged female with no suspected or diagnosed endometriosis. * Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day. * At least 18 years old

    Other: No Intervention

Interventions

  • OtherNo Intervention

    There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.

06

What researchers measure

Primary outcomes

  1. Deep Dyspareunia Score

    Self reported response to the question: "In the last 24 hours, how painful was deep penetration during sexual intercourse?" on an 11-point numeric rating scale (Not applicable (no intercourse), 0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the deep dyspareunia scores in the prospective 6 week period was calculated.

    Time frame: Case only: daily for 6 weeks after QST testing date

Secondary outcomes

  1. Superficial Dyspareunia Score

    Self reported response to the question: "In the last 24 hours, how painful was initial penetration (entry) during sexual intercourse?" on an 11-point numeric rating scale (Not applicable (no intercourse), 0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the superficial dyspareunia scores in the prospective 6 week period was calculated.

    Time frame: Case only: daily for 6 weeks after QST testing date

  2. Chronic Pelvic Pain Score

    Self reported response to the question: "What was your average level of pelvic pain in the last 24 hours?" on an 11-point numeric rating scale (0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the chronic pelvic pain scores in the prospective 6 week period was calculated.

    Time frame: Case only: daily for 6 weeks after QST testing date

07

Results

Posted Apr 8, 2026
Limitations and caveats
* small sample size due to difficulty with recruitment * the lack of multiple QST modalities * absence of pelvic test site in the assessment * results may not be generalizable to the general population since the participants were from a tertiary center for endometriosis * we included people on hormonal therapy, in order to capture representative endometriosis population, however due to the limited sample size we were not able to control for hormonal effects

Participant flow

Case participants: People with endometriosis from a tertiary endometriosis care center were approached after their baseline visit with their gynecologist and recruited for the study. Control participants: People with no suspected/diagnosed endometriosis and no pelvic pain scores above 4/10 were recruited from poster advertisements, in-person information sessions, and institutional research newsletters at the BC Women's Hospital.

Participant flow — Overall Study
MilestoneCaseControl
Started3719
Completed3619
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryDeep Dyspareunia Score

Self reported response to the question: "In the last 24 hours, how painful was deep penetration during sexual intercourse?" on an 11-point numeric rating scale (Not applicable (no intercourse), 0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the deep dyspareunia scores in the prospective 6 week period was calculated.

Time frame:
Case only: daily for 6 weeks after QST testing date
Reported as:
Mean · scores on a scale
Deep Dyspareunia Score
scores on a scaleCase
Low (<5)3.08 ± 2.32
SecondarySuperficial Dyspareunia Score

Self reported response to the question: "In the last 24 hours, how painful was initial penetration (entry) during sexual intercourse?" on an 11-point numeric rating scale (Not applicable (no intercourse), 0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the superficial dyspareunia scores in the prospective 6 week period was calculated.

Time frame:
Case only: daily for 6 weeks after QST testing date
Reported as:
Mean · scores on a scale
Superficial Dyspareunia Score
scores on a scaleCase
Superficial Dyspareunia Score2.34 ± 2.34
SecondaryChronic Pelvic Pain Score

Self reported response to the question: "What was your average level of pelvic pain in the last 24 hours?" on an 11-point numeric rating scale (0= no pain, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10= worst pain imaginable). The average of the chronic pelvic pain scores in the prospective 6 week period was calculated.

Time frame:
Case only: daily for 6 weeks after QST testing date
Reported as:
Mean · scores on a scale
Chronic Pelvic Pain Score
scores on a scaleCase
Chronic Pelvic Pain Score2.68 ± 1.76

Adverse events

Collected over During test day (QST) appointment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Case0/36 (0%)0/36 (0%)0/36 (0%)
Control0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)CaseControlTotal
Mean33 ± 731 ± 832 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)CaseControlTotal
Female361955
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CaseControlTotal
White231336
Other13619
Pain-pressure threshold
Pain-pressure threshold(Newtons)CaseControlTotal
Deltoid15.3 ± 6.914.6 ± 5.715.1 ± 6.5
First dorsal interosseous14.5 ± 7.711.9 ± 7.113.6 ± 7.5
Bladder and/or pelvic floor tenderness
Bladder and/or pelvic floor tenderness(Participants)CaseControlTotal
Bladder and/or pelvic floor tenderness11011
No bladder or pelvic floor tenderness25025
08

Study locations

1 site
  • BC Children's and Women's Hospital
    Vancouver, British Columbia V6H2N9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Apr 2019, 20 months.

Results were first posted in Apr 2026, 7 years after primary completion.

Of 155 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 20 months is below that.

Counting every sponsor, half of 182 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2017
First posted
Jul 13, 2017
StartActual
Jul 19, 2017
Primary completionActual
Apr 1, 2019
CompletionActual
Apr 1, 2019
Results first posted
Apr 8, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03216330
Lead sponsor
BC Women's Hospital & Health Centre
Responsible party
Paul Yong (Principal Investigator and Research Director, BC Women's Centre for Pelvic Pain and Endometriosis., BC Women's Hospital & Health Centre) — Principal investigator
First posted
Jul 13, 2017
Start date
Jul 19, 2017
Primary completion
Apr 1, 2019
Completion
Apr 1, 2019
Results posted
Apr 8, 2026
Last update
Apr 8, 2026

Study contacts

Paul Yong, MD/PhD
principal investigator · BC Children's and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion